C10-C11 Ester Inhibits Sepsis Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis are inadequate in effectively managing the inflammatory response and preventing organ damage, despite advancements in critical care and immunotherapies.
Innovation Solution
The use of synthetic fatty acids and their mono-, di-, and tri-esters with 1,2,3-propanetriol, specifically those with a double bond at the C10-C11 position, which inhibit proinflammatory cytokine secretion and signaling in macrophages, thereby addressing the inflammatory cascade contributing to sepsis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunotherapies and critical care management are used for sepsis treatment, then some inflammatory response control is achieved, but organ damage and mortality remain high due to inadequate suppression of the proinflammatory cascade
Solution Approach 1:
The patent modifies the chemical structure of fatty acids by introducing a specific double bond configuration at the C10-C11 position and esterifying with 1,2,3-propanetriol to create compounds with optimized anti-inflammatory parameters. This structural parameter change enables the compounds to effectively inhibit proinflammatory signaling pathways in macrophages, thereby improving treatment reliability while reducing organ damage.
Solution Approach 2:
The invention creates composite molecular structures by combining 1,2,3-propanetriol with specific fatty acid chains (C11-C24) containing a double bond at C10-C11. This composite structure integrates the beneficial properties of both components: the triol backbone provides structural framework while the specific fatty acid chains confer potent anti-inflammatory activity against the proinflammatory cascade.
2Object-affected harmful factors
If anti-inflammatory treatment is applied to suppress the inflammatory response in sepsis, then organ damage is prevented, but the ability to eliminate invading microorganisms may be compromised
Solution Approach 1:
The patent employs compounds that exert partial anti-inflammatory action by selectively targeting the proinflammatory cascade pathways responsible for organ damage while preserving the beneficial inflammatory responses needed for pathogen elimination. The specific C10-C11 double bond configuration enables selective modulation of macrophage signaling to achieve this partial action effect.
Solution Approach 2:
The synthetic fatty acid esters act as intermediary molecules that mediate between the immune system's need to fight infection and the need to prevent excessive inflammation. These compounds intervene in the proinflammatory signaling pathways of activated macrophages, dampening harmful signals while allowing protective immune functions to continue.
Data Source
AI summary
Compounds for use in the treatment of sepsis and/or the prevention or treatment of post-sepsis syndrome.